11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 28.05.2026 Expectation: 2500 pips
USDJPY sell-off targets 156.50 amid weakening upward momentum
Today at 10:19 AM 19
Period: 28.05.2026 Expectation: 70 pips
Buying SPX up to $7,500
Today at 09:19 AM 21
Gold buy
Period: 30.06.2026 Expectation: 1100 pips
Invest in gold on market optimism
Today at 08:52 AM 35
Period: 30.06.2026 Expectation: 650 pips
Selling AUDUSD upon breaching 0.7100
Today at 08:52 AM 12
Period: 21.06.2026 Expectation: 14600 pips
Selling ETHUSD down to $2,000
Today at 08:40 AM 13
Gold buy
Period: 28.05.2026 Expectation: 14000 pips
Buy gold with $4,680 in sight as oil finds its footing
Today at 05:55 AM 17
Go to forecasts